TY - JOUR T1 - Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications JF - European Journal of Hospital Pharmacy JO - Eur J Hosp Pharm SP - 310 LP - 312 DO - 10.1136/ejhpharm-2018-001711 VL - 27 IS - 5 AU - María Núñez-Núñez, PharmD, MsC AU - Inmaculada Casas-Hidalgo AU - Ricardo García-Fumero AU - Inmaculada Vallejo-Rodríguez AU - Francisco Anguita-Santos AU - José Hernández-Quero AU - José Cabeza-Barrera AU - Andrés Ruiz-Sancho Y1 - 2020/09/01 UR - http://ejhp.bmj.com/content/27/5/310.abstract N2 - Very limited labelled indications have been approved for the newer antimicrobials. Data on the clinical uses, efficacy and safety of dalbavancin are scarce, thus here we sought to describe our clinical experience. 16-month observational prospective study was performed. 19 (86%) were used under off-label indications. 10 (46%) for osteoarticular infections, 5 (23%) bloodstream infections and 3 (14%) endocarditis. To highlight, one patient received dalbavancin as long-term suppressive therapy. Most frequent use reasons were promptly hospital discharge, 11 (65%), and the presence of resistant organisms involving limited treatment options, 5 (23%). Successful outcome was observed in >95% of the patients and only 1 (4.5%) adverse event was reported. Further evidence beyond labelled indications is urgently needed. Despite the limitations, dalbavancin appears to be a safe and efficient option for adult patients who have tried and/or failed other therapies due to multidrug-resistant Gram-positive organisms. ER -